{"id":143574,"date":"2023-04-05T09:26:32","date_gmt":"2023-04-05T13:26:32","guid":{"rendered":"https:\/\/44.250.171.167\/?p=143574"},"modified":"2023-04-05T09:26:34","modified_gmt":"2023-04-05T13:26:34","slug":"can-jubilant-pharmova-leverage-their-position","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/can-jubilant-pharmova-leverage-their-position\/","title":{"rendered":"Can Jubilant Pharmova leverage their position?"},"content":{"rendered":"\n

\u201cIn FY24, Company\u2019s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in Generics, API businesses and Radiopharmacies will also contribute to better profitability. The Company has several growth levers across its various businesses of Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics and CRDMO, which shall drive sustainable growth for the company in the medium term. In our Proprietary Novel Drugs business we have several high potential programs, which are at the preclinical \/ clinical\u00a0 stage.\u201d<\/em><\/p>– Mr. Shyam S. Bhartia, Chairman<\/em><\/cite><\/blockquote>\n\n\n\n

Stock Data<\/strong><\/td><\/tr>
Ticker<\/strong><\/td>JUBLPHARMA<\/strong><\/td><\/tr>
Exchange<\/strong><\/td>NSE<\/strong><\/td><\/tr>
Industry<\/strong><\/td>PHARMACEUTICAL<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
Price Performance<\/strong><\/td><\/tr>
Last 5 Days<\/strong><\/td>+5.72%<\/strong><\/td><\/tr>
YTD<\/strong><\/td>-19.6%<\/strong><\/td><\/tr>
Last 12 Months<\/strong><\/td>-36.84%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

*As of 05.04.2023<\/p>\n\n\n\n

Company Description:<\/strong><\/h2>\n\n\n\n

Jubilant Pharmova Limited operates in the pharmaceutical and life science industries. The company has a diversified product portfolio that includes pharmaceuticals, contract manufacturing services, proprietary products, and drug discovery and development services. The company’s pharmaceutical business is primarily focused on the development, manufacture, and marketing of APIs (Active Pharmaceutical Ingredients) and finished dosage forms. The company’s contract manufacturing services business provides services for manufacturing and development of APIs and intermediates for both domestic and international markets. The company’s proprietary products business develops and markets branded formulations in the Indian market. The company’s drug discovery and development services business offers services for drug discovery and development to pharmaceutical and biotech companies worldwide. The company has seen consistent revenues even in times of turmoil.<\/p>\n\n\n\n

\"\"<\/a><\/figure><\/div>\n\n\n\n


Key Business Segments:<\/strong><\/h2>\n\n\n\n
  • Radiopharmaceuticals: <\/strong>Jubilant is very well positioned in a highly niche segment, manufacturing and distributing diagnostic imaging and therapeutic radiopharmaceutical products. In this segment, the firm has a strong grasp on the majority market share. The radio pharmacy business is about scale and the margins are much thinner than in the manufacturing of radiopharmaceuticals.

    The company is executing a detailed turnaround plan to grow top-line strongly with new customer wins, expand network to service newer geographies, increase product basket and enhance cost and procurement efficiencies. The Company is well positioned in the North American nuclear medicine market, which is expected to grow across the therapeutic segments of oncology, neurology and cardiology over the next five years. The Company aspires to be the leading manufacturer of nuclear medicine products in North America.<\/li><\/ul>\n\n\n\n
    • Generics: <\/strong>The company primarily focuses on the manufacture and sale of solid dosage formulations for CVS, CNS, GI and anti-allergy therapeutic categories. Within the United States, Jubilant is market leaders based on market share for several key products. Currently, margins have gone down a fair bit since then, with increased competition in the generic market. Moreover, the consolidation on the customer side has led to more bargaining power for the customers and put pricing pressure on the manufacturers.<\/li><\/ul>\n\n\n\n
      • Contract Manufacturing of Sterile and Non Sterile Products (CMO): <\/strong>Jubilant has an established position in this market and sees this business growing, due to the increased consolidation, with large pharma companies buying CMOs, and reducing their ability to service other customers, hence leading to a demand-supply disequilibrium in the market.  Jubilant has long term relationships with their top customers, with 6 of their top 10 customers having been customers for 10 years or more.<\/li><\/ul>\n\n\n\n


        Key Opportunities:<\/strong><\/h2>\n\n\n\n
        • Expansion of Contract Manufacturing Services:<\/strong> The global pharmaceutical outsourcing market is expected to grow at a CAGR of 6.7% between 2021 and 2028. Jubilant Pharmova Limited’s contract manufacturing services business is well-positioned to take advantage of this growth opportunity, given its established manufacturing capabilities and experience in the industry.<\/li><\/ul>\n\n\n\n
          • Increasing demand for generic drugs:<\/strong> The demand for generic drugs is increasing globally, driven by rising healthcare costs and aging populations. Jubilant Pharmova Limited’s strong presence in the generic drugs market in India and other countries positions it well to benefit from this trend.<\/li><\/ul>\n\n\n\n
            • Growth in emerging markets: <\/strong>Emerging markets, such as China and India, are expected to become major players in the pharmaceutical and life science industries in the coming years. Jubilant Pharmova Limited’s existing presence in these markets gives it a significant advantage in capturing this growth opportunity.<\/li><\/ul>\n\n\n\n
              • Increased focus on research and development:<\/strong> The company’s strong focus on research and development provides an opportunity to develop new products, improve existing products, and expand its product portfolio. The company’s drug discovery and development services business is well-positioned to benefit from the growing demand for these services.<\/li><\/ul>\n\n\n\n
                • Strategic acquisitions:<\/strong> The company has a history of making strategic acquisitions to expand its product portfolio and market reach. Further strategic acquisitions could provide opportunities for growth and expansion in new markets or product areas.<\/li><\/ul>\n\n\n\n

                  Jubilant Pharmova Limited is a well-diversified company operating in the pharmaceutical and life science industries. The company has a strong financial performance, a diversified product portfolio, and a focus on research and development. The company’s contract manufacturing services business is expected to be a key growth driver, and the company’s strong financial position and operational efficiencies are expected to drive further growth in the future. Overall, Jubilant Pharmova Limited is a well-managed company with a strong growth outlook<\/p>\n","protected":false},"excerpt":{"rendered":"

                  \u201cIn FY24, Company\u2019s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in Generics, API businesses and Radiopharmacies will also contribute to better profitability. The Company has several growth levers across its various businesses of Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics and CRDMO, which shall […]<\/p>\n","protected":false},"author":1885,"featured_media":138549,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5747,6352],"tags":[10162],"class_list":["post-143574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-stocks","category-research-summary","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":134521,"url":"https:\/\/alphastreet.com\/india\/everything-you-need-to-know-about-jubilant-pharmova\/","url_meta":{"origin":143574,"position":0},"title":"Everything you need to know about Jubilant Pharmova","author":"Chirag Gupta","date":"October 6, 2022","format":false,"excerpt":"About Company and its Outlook:\u00a0 Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. The Jubilant group operates these businesses through various subsidiaries that includes: Jubilant Pharma: This acts as their holding company for the\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":140186,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-limited-jublpharma-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":143574,"position":1},"title":"Jubilant Pharmova Limited (JUBLPHARMA ) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 6, 2023","format":false,"excerpt":"Jubilant Pharmova Limited (NSE:JUBLPHARMA) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Vineet Mayer\u00a0--\u00a0Investor Relations and Corporate Finance Shyam S Bhartia\u00a0--\u00a0Chairman Arun Sharma\u00a0--\u00a0Chief Financial Officer Pramod Yadav\u00a0--\u00a0CEO - Speciality and Sterile Injectables, Jubilant Pharma Jaidev Rajpal\u00a0--\u00a0Managing Director and Chief Executive Officer, Jubilant Generics Limited Giuliano Perfetti\u00a0--\u00a0CEO - CRDMO\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":134481,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-reports-dip-in-its-net-profit-by-71-for-q1fy23\/","url_meta":{"origin":143574,"position":2},"title":"Jubilant Pharmova reports dip in its net profit by 71% for Q1FY23","author":"Chirag Gupta","date":"October 3, 2022","format":false,"excerpt":"Jubilant Pharmova reported total income of INR 1,452 crores during the period ended June 30, 2022 as compared to INR 1,635 crores during the period ended June 30, 2021 depicting a dip of 11% while the net profit further plummeted by 71% as the company posted net profit INR 47\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135054,"url":"https:\/\/alphastreet.com\/india\/jubilant-pharmova-reports-dip-in-its-net-profit-by-97-for-q2fy23\/","url_meta":{"origin":143574,"position":3},"title":"Jubilant Pharmova reports dip in its net profit by 97% for Q2FY23","author":"Chirag Gupta","date":"October 24, 2022","format":false,"excerpt":"Jubilant Pharmova reported total income of INR 1,599.5 crores during the period ended September 30, 2022 as compared to INR 1,657.7 crores during the period ended September 30, 2021 depicting a dip of 3% while the net profit further plummeted by 97% as the company posted net profit INR 5\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":143040,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-jubilant-pharmova-limited-for-q3-fy23\/","url_meta":{"origin":143574,"position":4},"title":"Earnings Summary Of Jubilant Pharmova Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 28, 2023","format":false,"excerpt":"Jubilant Pharmova Limited (NSE: JUBLPHARMA) was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in November 2020. The company was founded in 1978 and is headquartered in Noida, India. It has a presence in over 100 countries worldwide and operates through several subsidiaries\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":145424,"url":"https:\/\/alphastreet.com\/india\/windlas-biotech-limited-windlas-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":143574,"position":5},"title":"Windlas Biotech Limited (WINDLAS) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 9, 2023","format":false,"excerpt":"Windlas Biotech Limited (NSE:WINDLAS) Q4 FY23 Earnings Concall dated May. 08, 2023. Corporate Participants: Hitesh Windlass\u00a0--\u00a0Managing Director Komal Gupta\u00a0--\u00a0Chief Executive Officer & Chief Financial Officer Analysts: Yogesh Tiwari\u00a0--\u00a0Arihant Capital Markets -- Analyst Raghav Vedanarayanan\u00a0--\u00a0JM Financial -- Analyst Naman Bhansali\u00a0--\u00a0Perpetuity Ventures LLP -- Analyst Gaurav Gandhi\u00a0--\u00a0Glorytail Capital Management -- Analyst Dipti\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1885"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=143574"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/143574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/138549"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=143574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=143574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=143574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}